Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-01-07
2011-11-29
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S04400A, C436S023000, C436S024000, C436S024000, C435S375000
Reexamination Certificate
active
08067388
ABSTRACT:
A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.
REFERENCES:
patent: 5225212 (1993-07-01), Martin et al.
patent: 5575815 (1996-11-01), Slepian et al.
patent: 6262033 (2001-07-01), Morishita et al.
patent: 6271206 (2001-08-01), Pillai et al.
patent: 6303582 (2001-10-01), Eljamal
patent: 6559168 (2003-05-01), Marfat et al.
patent: 6821956 (2004-11-01), Dzau et al.
patent: 7034007 (2006-04-01), Nyce et al.
patent: 0 824 918 (1998-02-01), None
patent: 1 008 352 (2000-06-01), None
patent: 1 170 363 (2002-01-01), None
patent: 2002-193813 (2002-07-01), None
patent: WO 96/35430 (1996-11-01), None
patent: WO 01/57204 (2001-08-01), None
patent: WO 01/83713 (2001-11-01), None
Laitinen et al Pharmacological Research vol. 37(4):251-254, 1998.
Abe et al., “Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides,”FEBS Letters, 425(1):91-96 (1998).
Ardaillou et al., “Production et activite proinflammatoire de necrose tumorale alpha dans le glomerule,”L'Acadernie Nationale de Medecine, 179:103-116 (1995).
Attiga et al., “Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases,”Cancer Research, 60:4629-4637 (2000).
Baker et al., “Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging,”British Journal of Surgery, 87: 1215-1221 (2000).
Bene et al., “Subcellular Localization as a Limiting Factor for Utilization of Decoy Oligonucleotides,”Nucleic Acids Research, 32(19), e142, (2004).
Bond et al., “Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts,”Biochemical and Biophysical Research Communications, 264:561-567 (1999).
Bond et al., “Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB,”FEBS Letter, 435:29-34 (1998).
Brunner et al., “Single bilayer vesicles prepared without sonication physico-chemical properties,”Biochimica et Biophysica Acta Biomembranes, 455(2):322-331 (1976).
Chabaud et al., “Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis,”Cytokine, 12(7):1092-1099 (2000).
Chu et al., “The Stability of Different Forms of Double-Stranded Decoy DNA in Serum and Nuclear Extracts,”Nucleic Acids Research, 20:5857-5858, (1992).
Deamer, “Preparation and properties of ether-injection liposomes,”Annals of the New York Academy of Sciences, 308:250-258 (1978).
Denhardt, “Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy,”Critical Reviews in Oncogenesis, 7(3&4):261-269 (1996).
Eberhardt et al., “Amplification of IL-1β-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-κB and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways,”Journal of Immunology, 165:5788-5797 (2000).
Farias et al., “Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients,”International Journal of Cancer, 89:389-394 (2000).
Gaetani et al., “Metalloproteases and intracranial vascular lesions,”Neurological Research, 21:385-390 (1999).
Gambarotta et al., “Etsup-regulatesMETtranscription,”Oncogene, 13:1911-1917 (1996).
Griesenbach et al., “Cytoplasmic Deposition of NFκB Decoy Oligonucleotides is Insufficient to Inhibit Bleomycin-induced Pulmonary Inflammation,”Gene Therapy, 9:1109-1115, (2002).
Halloran et al., “Pathogenesis of Aneurysms,”Seminars in Vascular Surgery, 8(2):85-92 (1995).
Hayashi et al., “Enhanced expression of membrane type-1 matrix metalloproteinase in mesangial proliferative glomerulonephritis,”Journal of the American Society of Nephrology, 9:2262-2271 (1998).
Hernandez-Presa et al., “ACE Inhibitor Quinapril Reduces the Arterial Expression of NF-κB-Dependent Proinflammatory Factors but not of Collagen I in a Rabbit Model of Atherosclerosis”,American Journal of Pathology, 153:1825-1837 (1998).
Holmes et al., “Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat,”Journal of Surgical Research, 63:305-309 (1996).
Horikawa et al., “Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma,”Cancer, 89:715-723 (2000).
Ikeda et al , “Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography,”Clinical Cancer Research, 6:3290-3296 (2000).
Jeffery, P.K., “Differences and Similarities Between Chronic Obstructive Pulmonary Disease and Asthma,”Clinical and Experimental Allergy, 29(Suppl. 2):14-26, (1999).
Jia et al., “Suppression of human microvascular endothelial cell invasion and morphogenesis with synthetic matrixin inhibitors,”Angiogenesis: From the Molecular to Integrative Pharmacology, Edited by Maragoudakis, Kluwer Academic/Plenum Publishers, New York (2000).
Jiang, et al., “Invasiveness of Hepatocellular Carcinoma Cell Lines: Contribution of Hepatocyte Growth Factor, c-met, and Transcription Factor Ets-1,”Biochemical and Biophysical Research Communications, 286, pp. 1123-1130 (2001).
Kaneda et al., “The role of the activated form of matrix metalloproteinase-2 in urothelial cancer,”BJU International, 86:553-557 (2000).
Katz et al., “Abdominal Aortic Aneurysms,”Seminars in Vascular Surgery, 8(4):289-298 (1995).
Khaled et al., “Use of Phosphorothioate-Modified Oligodeoxynucleotides to Inhibit NF-κB Expression and Lymphocyte Function,”Clinical Immunology and Immunopathology, 86(2): 170-179, (1998).
Kim et al., “Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NF-κB-dependent pathway,”Biochemical and Biophysical Research Communications, 269:401-405 (2000).
Kmiec, Eric B., “Gene Therapy,”American Scientist, 87:240-243, 245-247, (1999).
Kraan et al., “Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis,”Arthritis & Rheumatism, 43(8):1820-1830 (2000).
Kuper et al., “β-amyloid binds to p75NTRand activates NFκB in human nueroblastoma cells,”Journal of Neuroscience Research, 54:798-804 (1998).
Lebruska et al., “Selection and Characterization of an RNA Decoy for Transcription Factor NF-κB,”Biochemistry, 38:3168-3174, (1999).
Lee et al.,FASEB Journal, 15:A663, #523.9, (2001).
Leff, Alan R., “Future Directions in Asthma Therapy,”Chest, 111:61S-68S, (1997).
Lin et al., “Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade,”Biochemical Pharmacology, 58:911-915 (1999).
Marti, “New strategy to treat glomerular inflammation by inhibition of mesangial cell matrix metallo
Aoki Motokuni
Kawasaki Tomio
Morishita Ryuichi
Ogihara Toshio
AnGes MG, Inc.
Haley Jr. James F.
McGarry Sean
Ropes & Gray LLP
LandOfFree
Decoy-containing pharmaceutical compositions and method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Decoy-containing pharmaceutical compositions and method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Decoy-containing pharmaceutical compositions and method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4305201